


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-75)	LENRISPODUN
PRONUNCIATION	len" ris poe' dun
THERAPEUTIC CLAIM	Treatment of Parkinson's disease, cardiovascular diseases, and other neurological and cardiovascular diseases

CHEMICAL NAMES

1. Cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2*H*)-one, 2-[[4-(6-fluoro-2-pyridinyl)phenyl]methyl]-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-, (6a*R*,9a*S*)-
2. (6a*R*,9a*S*)-2-[[4-(6-Fluoro-2-pyridinyl)phenyl]methyl]-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2*H*)-one

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₂₉ H ₂₆ FN ₇ O
MOLECULAR WEIGHT	507.6
TRADEMARK	None as yet
SPONSOR	Intra-Cellular Therapies, Inc.
CODE DESIGNATIONS	ITI-214; ITI-214F; IC200214
<u>CAS</u> REGISTRY NUMBER	1160521-50-5
UNII	3GBO34D1BE
WHO NUMBER	11635

SCS